Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: Major challenges in current practice

References

• Larson R A, Dodge R K, Burns C P, Lee E J, Stone R M, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995; 85: 2025–2037
   PubMed Web of Science ®Google Scholar
• Anonymous. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood 1996; 87: 3135–3142
   PubMed Web of Science ®Google Scholar
• Secker-Walker L M, Prentice H G, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol 1997; 96: 601–610
   PubMed Web of Science ®Google Scholar
• Ueda T, Miyawaki S, Asou N, Kuraishi Y, Hiraoka A, Kuriyama K, et al. Response-oriented individualized induction therapy with six drugs followed by four courses of intensive consolidation, 1 year maintenance and intensification therapy: the ALL90 study of the Japan Adult Leukemia Study Group. Int J Hematol 1998; 68: 279–289
   PubMed Web of Science ®Google Scholar
• Wetzler M, Dodge R K, Mrozek K, Carroll A J, Tantravahi R, Block A W, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the Cancer and Leukemia Group B experience. Blood 1999; 93: 3983–3993
   PubMed Web of Science ®Google Scholar
• Faderl S, Kantarjian H M, Thomas D A, Cortes J, Giles F, Pierce S, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma 2000; 36: 263–273
   PubMed Web of Science ®Google Scholar
• Thomas X, Danaila C, Le Q H, Sebban C, Troncy J, Charrin C, et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001; 15: 1811–1822
   PubMed Web of Science ®Google Scholar
• Gleissner B, Gokbuget N, Bartram C R, Janssen B, Rieder H, Janssen J W, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536–1543
   PubMed Web of Science ®Google Scholar
• Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002; 16: 1259–1266
   PubMed Web of Science ®Google Scholar
• Annino L, Vegna M L, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002; 99: 863–871
   PubMed Web of Science ®Google Scholar
• Chao N J, Blume K G, Forman S J, Snyder D S. Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1995; 85: 3353–3354
   PubMed Web of Science ®Google Scholar
• Cornelissen J J, Carston M, Kollman C, King R, Dekker A W, Lowenberg B, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572–1577
   PubMed Web of Science ®Google Scholar
• Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, et al. Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 867–872
   PubMed Web of Science ®Google Scholar
• Druker B J, Sawyers C L, Kantarjian H, Resta D J, Reese S F, Ford J M, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042
   PubMed Web of Science ®Google Scholar
• Ottmann O G, Druker B J, Sawyers C L, Goldman J M, Reiffers J, Silver R T, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971
   PubMed Web of Science ®Google Scholar
• Hermans A, Heisterkamp N, von Linden M, van Baal S, Meijer D, van der Plas D, et al. Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 1987; 51: 33–40
   PubMed Web of Science ®Google Scholar
• Chan L C, Karhi K K, Rayter S I, Heisterkamp N, Eridani S, Powles R, et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987; 325: 635–637
   PubMed Web of Science ®Google Scholar
• Clark S S, McLaughlin J, Timmons M, Pendergast A M, Ben-Neriah Y, Dow L W, et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 1988; 239: 775–777
   PubMed Web of Science ®Google Scholar
• Lugo T G, Pendergast A M, Muller A J, Witte O N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990; 247: 1079–1082
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006; 24: 460–466
   PubMed Web of Science ®Google Scholar
• Armstrong S A, Look A T. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 6306–6315
   PubMed Web of Science ®Google Scholar
• Faderl S, Kantarjian H M, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91: 3995–4019
   PubMed Web of Science ®Google Scholar
• Pui C H, Evans W E. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166–178
   PubMed Web of Science ®Google Scholar
• Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V, et al. Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998; 92: 2730–2741
   PubMed Web of Science ®Google Scholar
• Roy A, Bradburn M, Moorman A V, Burrett J, Love S, Kinsey S E, et al. Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: results of the Medical Research Council ALL 97 trial. Br J Haematol 2005; 129: 35–44
   PubMed Web of Science ®Google Scholar
• Barrett A J, Horowitz M M, Ash R C, Atkinson K, Gale R P, Goldman J M, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1992; 79: 3067–3070
   PubMed Web of Science ®Google Scholar
• Stockschlader M, Hegewisch-Becker S, Kruger W, Tom Dieck A, Mross K, Hoffknecht M, et al. Bone marrow transplantation for Philadelphia-chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1995; 16: 663–667
   PubMed Web of Science ®Google Scholar
• Sierra J, Radich J, Hansen J A, Martin P J, Petersdorf E W, Bjerke J, et al. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 1997; 90: 1410–1414
   PubMed Web of Science ®Google Scholar
• Marks D I, Bird J M, Cornish J M, Goulden N J, Jones C G, Knechtli C J, et al. Unrelated donor bone marrow transplantation for children and adolescents with Philadelphia-positive acute lymphoblastic leukemia. J Clin Oncol 1998; 16: 931–936
   PubMed Web of Science ®Google Scholar
• Snyder D S, Nademanee A P, O'Donnell M R, Parker P M, Stein A S, Margolin K, et al. Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission. Leukemia 1999; 13: 2053–2058
   PubMed Web of Science ®Google Scholar
• Arico M, Valsecchi M G, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998–1006
   PubMed Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron J M, Rigal-Huguet F, Blaise D, Thomas X, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia – results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357–2366
   PubMed Web of Science ®Google Scholar
• Esperou H, Boiron J M, Cayuela J M, Blanchet O, Kuentz M, Jouet J P, et al. A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society. Bone Marrow Transplant 2003; 31: 909–918
   PubMed Web of Science ®Google Scholar
• Lee S, Kim D W, Cho B, Kim Y J, Kim Y L, Hwang J Y, et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120: 145–153
   PubMed Web of Science ®Google Scholar
• Stirewalt D L, Guthrie K A, Beppu L, Bryant E M, Doney K, Gooley T, et al. Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation. Biol Blood Marrow Transplant 2003; 9: 206–212
   PubMed Web of Science ®Google Scholar
• Dunlop L C, Powles R, Singhal S, Treleaven J G, Swansbury G J, Meller S, et al. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 1996; 17: 365–369
   PubMed Web of Science ®Google Scholar
• Atta J, Fauth F, Keyser M, Petershofen E, Weber C, Lippok G, et al. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction. Bone Marrow Transplant 2000; 25: 97–104
   PubMed Web of Science ®Google Scholar
• Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2: 561–566
   PubMed Web of Science ®Google Scholar
• Savage D G, Antman K H. Imatinib mesylate – a new oral targeted therapy. N Engl J Med 2002; 346: 683–693
   PubMed Web of Science ®Google Scholar
• Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Hughes T P, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley M L, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432
   PubMed Web of Science ®Google Scholar
• Thomas D A, Faderl S, Cortes J, O'Brien S, Giles F J, Kornblau S M, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396–4407
   PubMed Web of Science ®Google Scholar
• Thomas D A, Faderl S, Cortes J, O'Brien S, Giles F, Garcia-Manelo G, et al. Outcome with the hyper-CVAD and imatinib mesylate regimen in Philadelphia (Ph) positive acute lymphocytic leukemia (ALL). Blood 2005; 106, abstract #1830
   Google Scholar
• Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004; 104: 3507–3512
   PubMed Web of Science ®Google Scholar
• Lee S, Kim Y J, Min C K, Kim H J, Eom K S, Kim D W, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005; 105: 3449–3457
   PubMed Web of Science ®Google Scholar
• Lee K H, Lee J H, Choi S J, Lee J H, Seol M, Lee Y S, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005; 19: 1509–1516
   PubMed Web of Science ®Google Scholar
• Ottmann O G, Wassmann B, Pfeifer H, Goekbuget N, Bug G, Brueck P, et al. Imatinib given concurrently with induction chemotherapy is superior to imatinib subsequent to induction and consolidation in newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (PH + ALL). Blood 2004; 104, abstract #685
   Web of Science ®Google Scholar
• Pfeifer H, Ottmann O G, Goekbuget N, Wunderle L, Brueck P, Giagounidis A, et al. A randomized phase II study of single-agent imatinib versus chemotherapy therapy in elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) including analysis of resistance patterns. Blood 2005; 106, abstract #1824
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Meloni G, Chiarenza A, Malagola M, Fabbiano F, et al. Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ ALL patients: results of the GIMEMA prospective study LAL0201. Blood 2004; 104, abstract #2739
   Web of Science ®Google Scholar
• Delannoy A, Lheritier V, Thomas X, Castaigne S, Rigal-Huguet F, Raffoux E, et al. Treatment of Philadelphia-positive acute lymphocytic leukemia (Ph+ ALL) in the elderly with imatinib mesylate (STI571) and chemotherapy. Blood 2005; 106, abstract #146
   Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878
   PubMed Web of Science ®Google Scholar
• Dombret H, Witz F, de Botton S, Cayuela J M, Delabesse E, Preudhomme C, et al. Imatinib combined with intensive HAM chemotherapy as consolidation of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). Preliminary results of the AFR03 phase I/II study. Blood 2004; 104, abstract #2741
   Web of Science ®Google Scholar
• Shimoni A, Kroger N, Zander A R, Rowe J M, Hardan I, Avigdor A, et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–297
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Ottmann O G, Cortes J, Wassman B, Wunderle L, Bhalla K, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph+ ALL). Blood 2005; 106, abstract #37
   Web of Science ®Google Scholar
• Sawyers C L, Kantarjian H, Shah N, Cortes J, Paquette R, Donato N, et al. Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: update of a phase I study. Blood 2005; 106, abstract #38
   Web of Science ®Google Scholar
• Ottmann O G, Martinelli G, Dombret H, Kantarjian H, Hochhaus A, Simonsson B, et al. A phase II study of dasatinib in patients with chronic myeloid leukemia (CML) in lymphoid blast crisis or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to imatinib: the ‘START-L’ CA180015 study. Blood 2005; 106, abstract #42
   PubMed Web of Science ®Google Scholar